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Abstract
Background: Inflammation has been linked to the etiology of many organ-specific cancers. Indirect
evidence suggests a possible role for inflammation in breast cancer. We investigated whether the
systemic inflammation induced by Freund's adjuvant (FA) promotes mammary carcinogenesis in a
rat model in which cancer is induced by the neu oncogene.
Methods: The effects of FA on hyperplastic mammary lesions and mammary carcinomas were
determined in a neu-induced rat model. The inflammatory response to FA treatment was gauged
by measuring acute phase serum haptoglobin. In addition, changes in cell proliferation and apoptosis
following FA treatment were assessed.
Results: Rats receiving FA developed twice the number of mammary carcinomas as controls.
Systemic inflammation following FA treatment is chronic, as shown by a doubling of the levels of
the serum biomarker, haptoglobin, 15 days following initial treatment. We also show that this
systemic inflammation is associated with the increased growth of hyperplastic mammary lesions.
This increased growth results from a higher rate of cellular proliferation in the absence of changes
in apoptosis.
Conclusion: Our data suggests that systemic inflammation induced by Freund's adjuvant (FA)
promotes mammary carcinogenesis. It will be important to determine whether adjuvants currently
used in human vaccines also promote breast cancer.
Background
The etiology of breast cancer involves the interaction of
inherited risk with environmental exposure. Approxi-
mately 30% of breast cancer risk is inherited [1], the
majority of which is controlled by modifier genetic ele-
ments individually having low genetic penetrance, but
high population frequencies [2]. Our knowledge of envi-
ronmental factors that modulate breast cancer risk is quite
incomplete. The best documented association is for ioniz-
ing radiation, which carries the highest risk for breast can-
cer when exposure occurs prior to adulthood [3]. Other
known promoters of breast cancer include exogenously
administered hormonal replacement therapies [4].
Chronic inflammation arising from a variety of environ-
mental and infectious sources is associated with promo-
tion of many cancer types [5]. Evidence for chronic
inflammation in breast cancer etiology is supported by
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experimental [6] and epidemiological studies suggesting
that anti-inflammatory drugs can help prevent breast can-
cer [for review, see ref. [7]]. It thus can be hypothesized
that agents which induce a systemic inflammatory
response might increase breast cancer risk. The age win-
dow of maximum susceptibility to breast cancer initiation
by environmental radiation occurs before age 20 [3]. Dur-
ing this period of life, individuals are exposed to vaccine
adjuvants, which bolster the immune response to anti-
gens and often cause local and systemic inflammatory
responses. In order to begin to evaluate a role for systemic
inflammation in the etiology of breast cancer, Freund's
adjuvant (FA), which is known to induce both local and
systemic inflammation [8] was evaluated for its ability to
modulate breast cancer development in a rat model in
which cancer is induced by the neu oncogene.
Methods
Adjuvant treatments
All animal study protocols were approved by the Univer-
sity of Wisconsin Institutional Animal Care and Use Com-
mittee (IACUC). Virgin Wistar-Furth (WF) rats were
obtained from Harlan Sprague-Dawley (Indianapolis,
IN), housed in our facility on a 12 hour light/dark cycle
and given free access to standard lab chow. For all studies,
euthanasia was carried out using CO2 inhalation. Rats
were injected subcutaneously in the dorsal region with
Freund's complete adjuvant (CFA) or Freund's incomplete
adjuvant (IFA) (Sigma-Aldrich) suspended in sterile 0.9%
PBS. Three treatment protocols were used: early schedule,
late schedule and single dose. Rats on the early schedule
protocol received CFA (0.5 ml/kg body weight) at 5 weeks
of age and IFA (0.5 ml/kg body weight) at 7, 9 and 13
weeks of age. Rats on the late schedule were injected with
CFA at 10 weeks of age and IFA at 12 and 14 weeks. All
control groups received an equivalent volume of saline. In
the single dose model, CFA or saline was injected into 10
week old rats at a concentration of 0.5 ml/kg body weight,
and rats were euthanized 1 (n = 5/group) or 15 days (n =
6/group) after injection.
Mammary tumorigenesis
Virgin WF female rats were injected with adjuvant using
the early (n = 15) and late (n = 15) treatment protocols, as
described above. Controls (n = 14) received saline using
the early schedule. Mammary carcinomas were induced
by intraductal infusion of the pJRneu vector into the mam-
mary epithelium (12 glands/rat) of 8 week old rats, using
a viral titer of 1 × 105 CFU/ml. The generation and mam-
mary intraductal infusion of the pJRneu retroviral vector
has been previously described [9]. Rats were palpated
weekly for the presence of mammary carcinomas starting
at 9 weeks of age and removed from the study at 17 weeks
of age (9 weeks post-infusion). Mammary carcinoma mul-
tiplicity was recorded for each rat by counting the mam-
mary carcinomas greater than 3 mm in diameter.
To characterize hyperplastic mammary lesions in FA-
treated rats, the fourth mammary glands of rats on the
early treatment protocol (n = 20–21/group) were infused
with the pJRneu vector at a viral titer (1 × 107 CFU/ml).
This higher titer was previously determined to provide
sufficient statistical power, while minimizing the number
of required animals [10]. Rats were removed from the
study 15 days post-infusion, and one of the infused mam-
mary glands per rat was whole mounted and stained with
aluminum carmine as previously described [11]. Hyper-
plastic mammary lesions were identified from the whole
mounts by their size and counted using 20× light micros-
copy to determine lesion multiplicity. Each stained mam-
mary gland was photographed using a SONY Cybershot
digital camera using 1.3× optical zoom. The area of each
hyperplastic lesion, mammary gland and lymph nodes
was determined from digital photographs using ImageJ
(Scion Corp.), available from the NIH website http://
rsb.info.nih.gov/ij/. Two methods were used for statistical
comparison of area measurements from the hyperplastic
mammary lesions. First, the average lesion size was deter-
mined for each treatment (n = 179 lesions from controls
and 258 from adjuvant-treated rats). Secondly, the total
lesion area was determined for each mammary gland (n =
20–21/group) and normalized to its respective mammary
gland area. The normalized values were then combined
for each treatment group for statistical analysis. The con-
tralateral mammary glands (n = 10/group) were fixed in
10% neutral buffered formalin and stained with hematox-
ylin and eosin for histopathological analysis.
Evaluation of inflammatory response to adjuvant
Acute phase serum haptoglobin levels were measured in
rats injected with CFA or saline using the single dose pro-
tocol, as described above. Following euthanasia, blood
was collected from the aorta using a syringe and an 18
gauge needle and allowed to clot. Serum was collected
after centrifugation, aliquotted and stored at -80°C. Hap-
toglobin levels were determined using the Tri-Delta Diag-
nostics phase haptoglobin colorimetric assay, according
to the manufacturers' instructions. All samples, including
standards, were run in triplicate.
Immunohistochemical analysis for cell proliferation/
apoptosis
Mammary epithelial cell proliferation was evaluated by
immunohistochemistry for Ki67 in non-infused mam-
mary glands from rats on the early adjuvant schedule, and
from hyperplastic mammary lesions in virally infused rats
given early treatment of either adjuvant or saline. All rats
were sacrificed at 10 weeks of age. All reagents for Ki67
staining were obtained from Vector Laboratories unlessBMC Cancer 2009, 9:19 http://www.biomedcentral.com/1471-2407/9/19
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otherwise stated. Sections were immersed in antigen
retrieval solution at 95°C for 20 minutes following depar-
affinization in xylene and rehydration in decreasing con-
centrations of ethanol. Endogenous peroxide activity was
inhibited by incubation with 3% H202, and nonspecific
antibody binding was prevented by treating with 10%
normal goat serum and avidin/biotin blocking solutions.
Sections were incubated at 4°C overnight with a 1/500
dilution of mouse monoclonal anti-Ki67 antibody. After
washing with PBS, sections were then incubated with a 1/
200 dilution of biotinylated anti-mouse IgG. Detection of
Ki67 antibody binding was done using a Vectastain ABC
kit with DAB chromogen (BD Biosciences Pharmingen).
The fraction of proliferating epithelial cells in mammary
structures was determined by counting Ki67+ and Ki67-
cells magnified 200× with a light microscope (Olympus
BX50) and photographed using a digital camera with
Magnafire image capture software (Optronics). In the
mammary glands of rats given adjuvant (n = 8) or saline
(n = 7) without retroviral infusion, terminal end buds
(TEB) and ducts/alveolar structures were analyzed as sep-
arate compartments. All TEBs present in each section (80
control and 47 adjuvant-treated) were analyzed. For other
ductal and alveolar structures, all epithelial cells present
in 8–10 random fields (200×) per slide (n = 6/group)
were analyzed. For rats infused with neu, epithelial cell
counts were done from digital photos taken at 40× mag-
nification of the sections of the hyperplastic mammary
lesions (n = 10 rats/group). All lesions with adequate
staining were analyzed, for a total of 29 controls and 22
adjuvant-treated.
Apoptosis was assessed in hyperplastic mammary lesions
by labeling of 5' ends of fragmented DNA with terminal
deoxynucleotidyl transferase (TdT) enzyme using a TdT-
FragEL kit, following the manufacturers' instructions
(Oncogene/Invitrogen). The fraction of apoptotic epithe-
lial cells in hyperplastic mammary lesions was deter-
mined as described for Ki67.
Statistics
All statistical analyses were done using StatView (SAS,
Cary, NC). Mammary carcinoma multiplicity was tested
using One-Way ANOVA with Bonferroni-Dunn multiple
comparison. Serum haptoglobin, cell proliferation/apop-
tosis immunohistochemistry and hyperplastic mammary
lesion multiplicity were analyzed by unpaired t test and
nonparametric (Mann Whitney) testing, where appropri-
ate. Statistical analysis of serum haptoglobin values was
done separately for the two time points (1 day and 15
days), since each had its own control group. Area meas-
urements (mammary gland, lymph node and hyperplastic
mammary lesions) were analyzed by unpaired t test both
as raw data and following log transformation to more
closely approximate a normal distribution. Since the con-
clusions were the same for raw and log transformed data,
we present the results for the raw data.
Results
Adjuvant treatment increases incidence of mammary 
carcinomas following infusion of activated neu
Direct transfer of the neu oncogene into the mammary
ductal cells results in clonal development of mammary
carcinomas (Figure 1A and 1B) [12,13]. This model thus
provides a unique system to assess the effects of chronic
inflammation on breast cancer development. Treatment
of rats with adjuvant using either the early or late schedule
resulted in significantly increased mammary tumor multi-
plicity following infusion with neu compared with saline
controls (Figure 1C). At 9 weeks after ductal infusion,
adjuvant-treated rats had approximately twice the number
of carcinomas than did the controls (P < 0.05). There were
no histopathological differences between mammary carci-
nomas arising in the various treatment groups.
Adjuvant treatment induces a systemic and chronic 
inflammatory response and increases mammary epithelial 
cell proliferation
To assess for evidence of chronic systemic inflammation,
we measured serum haptoglobin concentrations [8]. Hap-
toglobin was elevated (~4-fold) 24 hours after a single
injection of CFA and was approximately 2-fold higher
than controls 15 days after injection (P < 0.01) (Figure 2).
Since a systemic inflammatory response was present, we
hypothesized that the products of inflammation, such as
cytokines and growth factors, may affect proliferation in
the mammary epithelium. In adjuvant-treated rats on the
early schedule protocol without retroviral infusion, stain-
ing for Ki67 showed a modest but statistically significant
increase in proliferation in the mammary gland epithe-
lium compared to controls (P < 0.05) (Table 1). This was
true for both epithelial cells in terminal end buds and for
ductal/alveolar structures. Interestingly, we did not
observe an increase in inflammatory cells within the
mammary parenchyma of adjuvant-only treated rats.
Adjuvant treatment given prior to infusion of neu 
oncogene increases the size of hyperplastic mammary 
lesions by increasing cell proliferation
We characterized the proliferative effects of Freund's adju-
vant (early schedule treatment) on hyperplastic mam-
mary lesions by analyzing mammary glands 15 days after
neu infusion. This time point precedes the formation of
palpable tumors, which occurs 3–4 weeks post-infusion.
A histological section of a typical hyperplastic mammary
lesion is shown in Figure 3A. Lesion multiplicity was
higher in rats given adjuvant than in saline controls (12.3BMC Cancer 2009, 9:19 http://www.biomedcentral.com/1471-2407/9/19
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Adjuvant treatment increases neu-induced mammary carcinoma multiplicity Figure 1
Adjuvant treatment increases neu-induced mammary carcinoma multiplicity. A. Representative histologic section 
of mammary carcinoma 12 weeks post-infusion, hematoxylin and eosin (H&E) staining, 40× magnification. B. 200× magnifica-
tion of area defined by box in panel A. C. Rats were injected subcutaneously with 0.5 ml/kg body weight Freund's complete 
adjuvant (CFA) at 5 (early schedule, n = 15) or 10 (late schedule, n = 15) weeks of age. Booster injections of Freund's incom-
plete adjuvant (IFA) were given at 7, 9, and 13 (early schedule) or 12 and 14 (late schedule) weeks of age. Controls received 
saline on the early schedule (n = 14). Rats were palpated weekly for carcinoma development following the infusion of the 
pJRneu retroviral vector into the mammary ducts at 8 weeks of age and euthanized 9 weeks post-infusion. *P < 0.05 compared 
with controls, One-Way ANOVA with Bonferroni-Dunn multiple comparisons.BMC Cancer 2009, 9:19 http://www.biomedcentral.com/1471-2407/9/19
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versus 8.9 respectively) but did not differ statistically (P =
0.13, unpaired t test).
The average size of the hyperplastic mammary lesions
determined from area measurements was significantly
higher (1.6-fold) in adjuvant-treated rats when compared
to controls (P < 0.001) (Figure 3B). In addition, the total
lesion area per mammary gland (normalized to mam-
mary gland area) was higher (~2-fold) in adjuvant-treated
rats versus controls (P < 0.01) (Figure 3C). The larger
lesion size led us to evaluate cell proliferation and apop-
tosis using immunohistochemistry. The epithelial cells
within the hyperplastic mammary lesions were signifi-
cantly more proliferative in adjuvant-treated rats, as deter-
mined by the percentage of Ki67+ cells, than in controls
(P < 0.001) (Table 1). The apoptotic fraction of cells in the
hyperplastic mammary lesions was low, and did not differ
significantly between saline (1.2%) and adjuvant (1.9%)
groups (P = 0.31, Mann-Whitney Rank test).
In addition to adjuvant-induced proliferation, we also
observed localized lymphadenopathy 15 days after neu
infusion in adjuvant-treated rats. The average area of
lymph nodes residing in the fourth mammary gland was
significantly higher (1.6-fold) in adjuvant-treated rats, as
compared to controls (P < 0.001) (Figure 3D).
Discussion
The role of local inflammation in the colon [14,15] and
prostate [16] in the etiology of these organ-specific can-
cers is well supported in humans. The role of inflamma-
tion in other cancer sites has been hypothesized. Here, we
used a rat model to show that systemic inflammation
induced by Freund's adjuvant (FA) can promote the devel-
opment of mammary carcinomas induced by neu, a gene
associated with breast cancer. This tumorigenic response
to FA was similar if given before or after the initiation of
carcinogenesis. This indicates that the effect of FA is not
due to altered infection efficiency of the neu viral vector.
FA administration produces a chronic state of systemic
inflammation, as determined by the serum haptoglobin,
an excellent cross-species marker for inflammation [8].
This finding is also supported by the observation of local-
ized mammary lymphadenopathy two weeks following
FA exposure.
Treatment with FA resulted in an increase in normal mam-
mary cell proliferation. Two weeks after initiating mam-
mary cancer with neu, many hyperplastic lesions are
found in the mammary gland, ranging in histopathologi-
cal progression from intraductal hyperplasia to ductal car-
cinoma in situ (DCIS) [9]. The main effect of FA-induced
inflammation on these lesions was to increase the prolif-
erative rate of these cells without significantly modifying
the apoptotic index. Thus, FA administration likely pro-
motes the growth of hyperplastic mammary lesions,
which may lead to an increase in carcinoma formation.
Adjuvant treatment acutely and persistently elevates circulat- ing haptoglobin concentrations in the serum Figure 2
Adjuvant treatment acutely and persistently elevates 
circulating haptoglobin concentrations in the serum. 
Rats were given a single subcutaneous injection of CFA, (0.5 
ml/kg body weight) and sacrificed 1 (n = 5/group) or 15 (n = 
6/group) days later. Error bars represent +1 SD. *P < 0.01, 
Mann-Whitney Rank test.
Table 1: Analysis of epithelial cell proliferation in mammary glands and neu-induced hyperplastic mammary lesions by Ki67 
immunohistochemistry
Percentage of Proliferating Cells ± SD
Treatment Terminal End Buds Ductal/Alveolar Structures Hyperplastic Mammary Lesions
Saline 56% ± 1 13% ± 1 None
Adjuvant 61% ± 1* 17% ± 1* None
Saline + neu N.A. N.A. 41% ± 2
Adjuvant + neu N.A. N.A. 55% ± 2**
N.A.= not analyzed
*P < 0.05, **P < 0.001 (Mann-Whitney Rank test)BMC Cancer 2009, 9:19 http://www.biomedcentral.com/1471-2407/9/19
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The presence of chronic inflammation suggests that the
immune system may mediate mammary lesion prolifera-
tion through systemic or local regulation of cytokines
and/or growth factors.
Conclusion
It is important to point out that FA is a very strong adju-
vant, and is not used in humans. However, weaker adju-
vants, such as aluminum salts, are routinely used in most
human vaccines for similar purposes [17]. In addition,
much work, including clinical trials, is now underway to
develop more potent and effective adjuvants for human
use [18]. Such adjuvants would have the potential to both
focus and intensify the immune response and also to
reduce the amount of vaccine antigen needed per vaccina-
tion. Since many vaccinations are given in childhood and
Adjuvant treatment increases the size of hyperplastic mammary lesions 15 days following neu infusion and results in localized  lymphadenopathy Figure 3
Adjuvant treatment increases the size of hyperplastic mammary lesions 15 days following neu infusion and 
results in localized lymphadenopathy. Rats were given 0.5 ml/kg body weight CFA at 5 weeks of age and booster injec-
tions IFA at 7 and 9 weeks of age (n = 21). Controls received saline (n = 20). Infusion of the neu oncogene retroviral vector 
into the fourth mammary gland was done at 8 weeks of age. A. H&E staining of a representative hyperplastic mammary lesion 
(100× magnification). B. Average lesion area determined for each treatment (n = 179 lesions from controls and 258 from adju-
vant-treated rats). C. Total lesion area per gland, normalized to individual mammary gland area (n = 20–21/group). D. Average 
area of the intramammary lymph nodes from infused glands (n = 20–21/group). Error bars represent +1 SD. *P < 0.001; **P < 
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adolescence, the times of greatest susceptibility to breast
cancer initiation [3], it will be important to evaluate the
safety of both currently used and new vaccine adjuvants in
experimental models and epidemiologic studies that
focus on breast cancer etiology.
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